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In addition to the generation of protec-
tive immune responses, effective immune 
defense strategies depend on intricate 
negative regulation to restrict tissue dam-
age due to inflammation. Interleukin-10 
(IL-10) is an immunosuppressive cyto-
kine produced by and acting on many 
different leukocytes, including dendritic 
cells (DCs) and T cells.1,2 In particular, 
regulatory T cells (Tregs) exert their 
immunosuppressive function largely via 
the secretion of IL-10. As a gatekeeper 
of excessive immune responses against 
foreign antigens, IL-10 is expressed at 
epithelial interfaces to the environment, 
including the skin. Consequently, IL10−/− 
mice develop increased contact hyper-
sensitivity (CHS),3 a relevant mouse 
model for allergic contact dermatitis.4 
Following the topical application of a 
contact sensitizer (hapten), DCs prime 
hapten-specific T cells in skin-draining 
lymph nodes (sdLNs). The subsequent 
painting of the same hapten onto the ears 
triggers a transient ear-swelling reaction, 
driven by interferon γ (IFNγ)-secreting 
T
H
1 cells and regulated by CD4+ T cells 
producing IL-10. Mice bearing a T cell- 
or Treg-specific deletion of IL10 exhibit 
aggravated CHS, demonstrating the 
essential role of T cell-derived IL-10 to 
curtail the inflammatory skin reaction.5,6 
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The cellular targets of IL-10 during CHS 
remain elusive.
DCs have the unique capacity to bal-
ance immunity and tolerance and hence 
are critical in the maintenance of immune 
homeostasis during infection/inflamma-
tion as well as in steady-state conditions.7 
DCs continuously probe their environ-
ment and induce robust, protective T-cell 
responses to pathogen-derived antigens as 
well as T-cell tolerance to innocuous for-
eign and self-antigens, for instance via the 
induction of Tregs. Besides Langerhans 
cells (LCs) in the epidermis, the skin 
harbors distinct dermal DC populations, 
and we recently established the functional 
redundancy of distinct cutaneous DC 
subsets in mediating CHS.8 During hap-
ten sensitization, the production of IL-10 
by LCs—and presumably also by dermal 
DCs—is required to limit ear swelling, as 
mice bearing a LC-specific IL10 knock-
out mount aggravated CHS responses.9 
Conversely, although IL-10 can inhibit 
DC maturation and skew DCs toward a 
tolerogenic phenotype in vitro, it is still 
unknown to what extent IL-10 controls 
DC function in vivo.
To address this question, we analyzed 
mice bearing a DC-specific deletion of 
the gene coding for the IL-10 receptor 
(DC-IL10R−/− mice), both in steady-state 
conditions and during CHS.10 We made 
several observations that shed new light 
on the molecular control of DCs by IL-10. 
First, IL-10 signaling in DCs is dispens-
able to maintain their immature phe-
notype in steady-state conditions.10 The 
surface expression of MHC Class II, co-
stimulatory and co-inhibitory molecules 
was not altered in IL-10R-deficient DCs. 
Accordingly, T cells in DC-IL10R−/− ani-
mals were non-activated and the frequency 
of Tregs was similar to that of wild type 
(WT) mice. Second, the control of DC by 
IL-10 is necessary to prevent aggravated 
CHS.10 In contrast to total and Treg-
specific IL10−/− mice,3,5,6 DC-IL10R−/− and 
WT mice developed a similar ear-swell-
ing reaction 24 h after hapten challenge. 
Intriguingly, at 48 h, ear swelling further 
increased in DC-IL10R−/− mice, while the 
inflammation began to resolve in WT 
animals. Third, IL-10 controls DC func-
tion during the effector phase of CHS.10 
The adoptive transfer of T cells primed 
in WT or DC-IL10R−/− donor mice into 
either type of recipient animals, confirmed 
similar ear swelling 24 h after hapten chal-
lenge. In contrast, at 48 h the ear-swell-
ing reaction was significantly stronger in 
DC-IL10R−/− recipients, whereas T cells 
that were primed by IL-10R-deficient and 
reactivated by WT DCs failed to elicit 
Interleukin-10 (IL-10) is a potent immunomodulatory cytokine, whose cellular targets have not yet been precisely 
identified. Dendritic cell (DC)-specific IL-10 receptor knockout mice exhibit exaggerated t-cell reactivation in the skin, 
highlighting a key role of DCs in the maintenance of local immune homeostasis, beyond their classical function as 
regulators of t-cell priming in lymph nodes.
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mature DC function by IL-10 is dispens-
able during T-cell priming. Second, DCs 
are the target of IL-10 to limit excessive 
T-cell reactivation during the elicitation of 
CHS, as demonstrated by the exaggerated 
ear swelling observed 48 h after hapten 
challenge in DC-IL10R−/− mice. In con-
trast to priming, the IL-10-mediated auto-
crine/paracrine negative feedback on DCs 
in situ is required to curtail inflammation 
and tissue damage. This highlights a criti-
cal role of skin DCs in the maintenance 
of immune homeostasis that goes beyond 
their classical function as migratory anti-
gen-presenting cells. Whether such DCs 
are resident and/or inflammatory remains 
to be determined. Finally, the exaggerated 
ear swelling observed at 48 h, despite the 
elevated expression of IL-10 in the skin, 
indicates that the regulation of T cells 
by IL-10 alone is inadequate to restrict 
adaptive immune responses in inflamed 
in both strains. Intriguingly, the increase 
in T cells observed from 24 to 48 h was 
mainly caused by the recruitment of 
FOXP3+ Tregs into the skin.
The major implications of these find-
ings are 3-fold (Fig. 1). First, the lack 
of IL-10 signaling in DCs does not alter 
T-cell priming in sdLNs during hapten 
sensitization. Most likely, the balanced, 
albeit elevated secretion of pro-inflam-
matory cytokines and inhibitory IL-10 
by IL-10R-deficient skin-infiltrating DCs 
drives a similar differentiation of effector 
cells and Tregs as in WT mice. Therefore, 
ear swelling in DC-IL10R−/− mice is not 
augmented 24 h after a hapten challenge. 
Accordingly, the production of IL-10 by 
LCs, which is essential to prevent exagger-
ated T-cell priming and ear swelling at 24 
h,9 exclusively acts on naïve T cells, rather 
than in an autocrine fashion. Moreover, 
the potential paracrine regulation of 
exaggerated ear swelling. Forth, IL-10R-
deficient DCs produce elevated amounts 
of cytokines after in vitro stimulation.10 
Although the activation of IL10R−/− and 
WT DCs by lipopolysaccharide (LPS) 
induced similar phenotypic maturation, 
according to surface marker expression, 
Il10r−/− DCs secreted increased amounts 
of tumor necrosis factor α (TNFα), IL-6 
and IL-10. Fifth, enhanced cytokine 
expression and cellular influx occur in 
the skin of DC-IL10R−/− animals during 
the elicitation of CHS.10 As soon as 24 h 
after a hapten challenge, the expression 
of pro-inflammatory cytokines and IL-10 
was increased in the skin of these ani-
mals as compared with their WT coun-
terparts, causing a massive infiltration 
of innate, MHC Class II+ and T cells at 
48 h. Whereas the global extent of infil-
tration was lower in WT mice, the num-
ber of skin-infiltrating T cells was similar 
Figure 1. the control of dendritic cells by interleukin-10 is dispensable during naïve t-cell priming in skin-draining lymph nodes, but essential to curtail 
excessive effector t-cell reactivation in the skin. During the sensitization phase, the topical application of a contact sensitizer (hapten) onto the skin 
induces the migration of dendritic cells (DCs) into skin-draining lymph nodes (sdLNs) for the priming of naïve hapten-specific t cells (left). the balanced 
production of interleukin-10 (IL-10) and pro-inflammatory cytokines induces the differentiation of appropriate effector t cells (teffs) and regulatory 
t cells (tregs), despite elevated cytokine secretion by IL-10 receptor-deficient DCs. IL-10 signaling in DCs is not required at the time of t-cell priming. 
During the elicitation of contact hypersensitivity (Chs), antigen-specific teffs and tregs are re-activated by DCs in the skin (right). In the absence of IL-10 
signaling in DCs this leads to enhanced ear swelling/inflammation, irrespective of an increased expression of IL-10 in situ. tn, naïve t cell.
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during T-cell priming but essential to limit 
the magnitude and duration of the effector 
CHS response.10 This regulatory function 
of DCs in the skin has significant impli-
cations for the immunotherapy of human 
diseases (e.g., cancer) since the release of 
DCs from the control mediated by IL-10 
tissues. Therefore, FOXP3+ Tregs prefer-
entially recruited into the skin 48 h after 
elicitation of CHS exert their regulatory 
function largely by IL-10 control of DCs 
and to a lesser extent of effector T cells.
In conclusion, our study establishes 
that IL-10 signaling in DCs is dispensable 
might promote their immunogenicity 
without increasing the risk for autoimmu-
nity due to enhanced T-cell priming.
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